These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 29307736)

  • 21. Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty.
    Ruan Q; D'Onofrio G; Sancarlo D; Greco A; Yu Z
    Mol Med Rep; 2016 Oct; 14(4):3184-98. PubMed ID: 27511317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease].
    Sakurai H; Hanyu H
    Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.
    Drago V; Babiloni C; Bartrés-Faz D; Caroli A; Bosch B; Hensch T; Didic M; Klafki HW; Pievani M; Jovicich J; Venturi L; Spitzer P; Vecchio F; Schoenknecht P; Wiltfang J; Redolfi A; Forloni G; Blin O; Irving E; Davis C; Hårdemark HG; Frisoni GB
    J Alzheimers Dis; 2011; 26 Suppl 3():159-99. PubMed ID: 21971460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
    Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
    Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach.
    Begcevic I; Brinc D; Brown M; Martinez-Morillo E; Goldhardt O; Grimmer T; Magdolen V; Batruch I; Diamandis EP
    J Proteomics; 2018 Jun; 182():12-20. PubMed ID: 29684683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].
    Verhey FR; Visser PJ
    Ned Tijdschr Geneeskd; 2013; 157(11):A5596. PubMed ID: 23484512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
    Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts.
    Schmand B; Eikelenboom P; van Gool WA;
    J Am Geriatr Soc; 2011 Sep; 59(9):1705-10. PubMed ID: 21883100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers.
    Vercruysse O; Paquet C; Gabelle A; Delbeuck X; Blanc F; Wallon D; Dumurgier J; Magnin E; Martinaud O; Jung B; Bousiges O; Lehmann S; Delaby C; Quillard-Murain M; Peoc H K; Laplanche JL; Bouaziz-Amar E; Hannequin D; Sablonniere B; Buee L; Hugon J; Schraen S; Pasquier F; Bombois S; For The E-Plm Group
    Curr Alzheimer Res; 2018; 15(7):691-700. PubMed ID: 29318973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.
    Herukka SK; Simonsen AH; Andreasen N; Baldeiras I; Bjerke M; Blennow K; Engelborghs S; Frisoni GB; Gabryelewicz T; Galluzzi S; Handels R; Kramberger MG; Kulczyńska A; Molinuevo JL; Mroczko B; Nordberg A; Oliveira CR; Otto M; Rinne JO; Rot U; Saka E; Soininen H; Struyfs H; Suardi S; Visser PJ; Winblad B; Zetterberg H; Waldemar G
    Alzheimers Dement; 2017 Mar; 13(3):285-295. PubMed ID: 28341066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
    Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
    Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Head Turning Sign in Dementia and Mild Cognitive Impairment: Its Relationship to Cognition, Behavior, and Cerebrospinal Fluid Biomarkers.
    Durães J; Tábuas-Pereira M; Araújo R; Duro D; Baldeiras I; Santiago B; Santana I
    Dement Geriatr Cogn Disord; 2018; 46(1-2):42-49. PubMed ID: 30092564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study.
    Scaricamazza E; Colonna I; Sancesario GM; Assogna F; Orfei MD; Franchini F; Sancesario G; Mercuri NB; Liguori C
    Neurol Sci; 2019 Jul; 40(7):1377-1382. PubMed ID: 30903419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
    Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
    Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress on early diagnosing Alzheimer's disease.
    Chen Y; Al-Nusaif M; Li S; Tan X; Yang H; Cai H; Le W
    Front Med; 2024 Jun; 18(3):446-464. PubMed ID: 38769282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.